Arthur He
Stock Analyst at HC Wainwright & Co.
(4.44)
# 321
Out of 5,182 analysts
51
Total ratings
55.56%
Success rate
29.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Maintains: Buy | $25 → $35 | $16.17 | +116.45% | 2 | Mar 25, 2026 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $7.74 | +158.40% | 11 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $90 → $110 | $40.45 | +171.97% | 4 | Mar 2, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $135 → $165 | $74.72 | +120.82% | 6 | Feb 10, 2026 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $4.32 | +62.04% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $16.00 | +6.25% | 1 | Jul 30, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.34 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $5.65 | - | 8 | Mar 31, 2025 |
Jade Biosciences
Mar 25, 2026
Maintains: Buy
Price Target: $25 → $35
Current: $16.17
Upside: +116.45%
Solid Biosciences
Mar 23, 2026
Reiterates: Buy
Price Target: $20
Current: $7.74
Upside: +158.40%
Vera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $40.45
Upside: +171.97%
Nektar Therapeutics
Feb 10, 2026
Maintains: Buy
Price Target: $135 → $165
Current: $74.72
Upside: +120.82%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.32
Upside: +62.04%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $16.00
Upside: +6.25%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.34
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.65
Upside: -